trans-4-OH CCNU | 52049-26-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: trans-4-OH CCNU
• 英文别名: 1-(2-chloroethyl)-3-(4-hydroxycyclohexyl)-1-nitrosourea
• CAS: 52049-26-0；56239-24-8
• 化学式: C₉H₁₆ClN₃O₃
• 分子量: 249.69
• InChiKey: BTNKSMIZKSHDNT-UHFFFAOYSA-N

物化性质

• 沸点：
  132°C (rough estimate)
• 密度：
  1.4460 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  82
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2924299090

制备方法与用途

类别：有毒物质
毒性分级：高毒
急性毒性：腹腔-小鼠 LD50: 60.18 毫克/公斤；静脉-小鼠 LD10: 25 毫克/公斤
可燃性危险特性：可燃，火场释放有毒氯化物及氮氧化物烟雾
储运特性：库房低温、通风干燥保存，并与食品原料分开存放
灭火剂：水、二氧化碳、泡沫、沙土

文献信息

• KIT FOR TREATMENT OF CANCER
  申请人：Redoxia Israel Limited

  公开号：EP1755679A2

  公开（公告）日：2007-02-28
• Kit for Treatment of Cancer
  申请人：Hoffman Arnold

  公开号：US20080287541A1

  公开（公告）日：2008-11-20

  The present invention relates to a kit for the treatment of cancer comprising (a) a container for containing a first compound (i) or a precursor thereof, said first compound or precursor being a compound that oxidizes glutathione (GSH); (b) a container for containing a second compound (ii) or a precursor thereof, said second compound or precursor being a compound that forms an adduct or conjugate with GSH; (c) a container for containing a third compound (iii) or a precursor thereof, said third compound or precursor being a compound that inhibits the rate-limiting enzyme of GSH biosynthesis, gamma-glutamylcysteine synthetase (GCS); and (d) a container for containing a fourth compound (iv) or a precursor thereof, said fourth compound or precursor being a compound that inhibits the enzyme responsible for the conversion of GSSG to GSH, glutathione reductase (GR).
• Multi-stage stem cell carcinogenesis
  申请人：Krtolica Ana

  公开号：US20100162416A1

  公开（公告）日：2010-06-24

  The present invention relates to a system of multi-stage stem cell carcinogenesis and a method of generating such multi-stage stem cell carcinogenesis system. Various stages of cancer stem cells can be generated from normal stem cells via mutagenesis. The system of the present invention enables monitoring changes in the ability of cells to transition from one stage of carcinogenesis to another and to identify genetic pathways and molecules that influence carcinogenesis. The present invention also enables a high-throughput and nonbiased screening for targets that preferentially affect cancer stem cells relative to non-cancer stem cells or their derivatives during stem cell carcinogenesis, thus is useful in developing anti-cancer therapeutics.
• [EN] KIT FOR TREATMENT OF CANCER<br/>[FR] KIT POUR LE TRAITEMENT DU CANCER
  申请人：REDOXIA ISRAEL LTD

  公开号：WO2005107370A2

  公开（公告）日：2005-11-17

  The present invention relates to a kit for the treatment of cancer comprising (a) a container for containing a first compound (i) or a precursor thereof, said first compound or precursor being a compound that oxidizes glutathione (GSH); (b) a container for containing a second compound (ii) or a precursor thereof, said second compound or precursor being a compound that forms an adduct or conjugate with GSH; (c) a container for containing a third compound (iii) or a precursor thereof, said third compound or precursor being a compound that inhibits the rate-limiting enzyme of GSH biosynthesis, Ϝ-glutamylcysteine synthetase (GCS); and (d) a container for containing a fourth compound (iv) or a precursor thereof, said fourth compound or precursor being a compound that inhibits the enzyme responsible for the conversion of GSSG to GSH, glutathione reductase (GR).
• [EN] MULTI-STAGE STEM CELL CARCINOGENESIS<br/>[FR] CARCINOGENESE DE CELLULES SOUCHES MULTIETAPES
  申请人：STEMLIFELINE INC

  公开号：WO2010037134A2

  公开（公告）日：2010-04-01

  The present invention relates to a system of multi-stage stem cell carcinogenesis and a method of generating such multi-stage stem cell carcinogenesis system. Various stages of cancer stem cells can be generated from normal stem cells via mutagenesis. The system of the present invention enables monitoring changes in the ability of cells to transition from one stage of carcinogenesis to another and to identify genetic pathways and molecules that influence carcinogenesis. The present invention also enables a high-throughput and nonbiased screening for targets that preferentially affect cancer stem cells relative to non-cancer stem cells or their derivatives during stem cell carcinogenesis, thus is useful in developing anti-cancer therapeutics.